As the dust settles on the eye-watering $14 billion buyout from Pfizer for the one-marketed-drug biotech Medivation, other mid-cap companies are now sitting…

Perceptive Advisors has co-led a $14 million Series C financing to get startup Vyome into clinical testing with its lead candidate to treat antibiotic-…

Startup Nutrinia has lined up an impressive roster of investors to back what has been a long elusive achievement—the development of oral insulin.

Tioma Therapeutics plans to use part of the massive infusion of cash from its Series A round to jump into the Bay Area from St. Louis, MO.

There may be a slightly wider crack in the biotech IPO window this summer as Protagonist Therapeutics announces a larger-than-expected offering.

Motif Bio has had its Nasdaq IPO hopes crushed by an unreceptive market, leaving the late-phase antibiotic player with a hole in its spending plans.

Cleave Biosciences aims to create novel small molecules that work to control protein homeostasis in order to treat blood and solid cancers. Now, oncology giant…

The value of Neil Woodford’s Patient Capital Trust fell 10.8% as Circassia’s late-phase flop and the ongoing decline of Northwest Biotherapeutics hit home.